Page 1

● Establishment ● Labs Coyol Free Zone & Business Park Building , 4th Street , Building B - 15 , Alajuela , COSTA RICA 1187 Coast Village Road , Suite 1-402 , Santa Barbara CA 93108 , USA Investor / Media Contact : Raj Denhoy 415 828-1044 EXHIBIT 99.1 PRESS RELEASE Establishment Labs Reports Record Second Quarter 2021 Financial Results and Raises Full Year Guidance rdenhoy@establishmentlabs.com SANTA BARBARA , Calif . , July 29 , 2021 -- Establishment Labs Holdings Inc. ( NASDAQ : ESTA ) , a global medical technology company dedicated to improving women's health and wellness , principally in breast aesthetics and reconstruction , today announced its financial results for the second quarter ended June 30 , 2021 and provided updated 2021 guidance . Second Quarter Highlights and Outlook Second quarter worldwide sales of $ 32.0 million , an increase of 205 % year - over - year and a new quarterly record ; results are in line with preannounced range of $ 31 million to $ 32 million provided on July 12 , 2021 . 2021 guidance increased to a new range of $ 122 million to $ 126 million , an increase of 44 % to 49 % over 2020 ; previous 2021 guidance range was $ 118 million to $ 122 million . Second quarter operating expenses of $ 26.1 million , an increase of 55 % compared to the second quarter of 2020 as spending returned to more normalized levels following the global disruption in 2020 . Total net cash burn of $ 1.1 million in the second quarter . Cash balance of $ 76.8 million as of June 30 , 2021 . Publication of landmark study in Nature Biomedical Engineering showing superior biocompatibility of Motiva® SmoothSilk® implant technology . Marketing and commercial activities with Motiva Ergonomix2® expanding . Commercial launch of Motiva Flora® tissue expander in Europe continuing . Motiva MIA® development and commercialization plans progressing as planned . Timelines for US and China market entry remain unchanged . Held groundbreaking on Sulàyöm Innovation Campus , which will expand manufacturing capacity to approximately 1.9 million implants per year when complete and add new capabilities in R & D , media , and medical education . " We delivered record second quarter revenue of $ 32.0 million , which was up 205 % from the second quarter of 2020 and 5 % sequentially from the first quarter of 2021 , " said Juan José Chacón - Quirós , Chief Executive Officer . " Our strong second quarter and first half financial results show that our business is in very good shape . With this momentum , we are sing full year 2021 revenue guidance to a new range of $ 122 million to $ 126 million . " " The second quarter was a productive period for Establishment Labs , " Mr. Chacón - Quirós continued . " The publication in late June of the paper " The surface topography of silicone breast implants mediates the foreign body response in mice , rabbits and humans " in Nature Biomedical Engineering was a watershed event for women's health . The paper showed that our bioengineered SmoothSilk surface reduces inflammation and produces the most biocompatible immune response compared to other implants . The findings add to a foundation of clinical and scientific data built over the last decade in the market and explains one of the key reasons our implants perform so well . " " As our core implant business continues to take share globally , we are expanding availability of our Ergonomix2 implant line and launching into reconstruction with our Motiva Flora tissue expander . In addition , market